

Attenuation of Cardiovascular Responses to Pneumoperitoneum and Reduction of Perioperative Haemodynamic Instability during Laparoscopic Surgery with Oral Clonidine Premedication.

Dr Subhashree Sahu¹, Dr Monalee Baviskar², Dr Shilpi Yadav³, Dr Archana Har⁴, Dr Madishatty Uday Kumar⁵

¹Junior Resident, Department of Anaesthesiology, MGM Medical College and Hospital, Kamothe ²Assistant Professor, Department of Anaesthesiology, MGM Medical College and Hospital, Kamothe ³Associate Professor, Department of Anaesthesiology, MGM Medical College and Hospital, Kamothe, Corresponding Author

⁴Professor, Department of Anaesthesiology, MGM Medical College and Hospital, Kamothe ⁵Junior Resident, Department of Anaesthesiology, MGM Medical College and Hospital, Kamothe

Date of Submission: 10-05-2024

Date of Acceptance: 20-05-2024

ABSTRACT

BACKGROUND: The cardiovascular changes with laparoscopy associated (during -carbon dioxide pneumoperitoneum gas insufflation) are an increase in systemic vascular resistance, mean arterial pressure, pulmonary vascular resistance, myocardial filling pressures accompanied by a fall in the cardiac index and tissue perfusion. These changes are not only related to the mechanical factors as they outlast the end of pneumoperitoneum. The neurohumoral factors like prostaglandins, catecholamines, the rennin angiotensin aldosterone system (RAAS), vasopressin are potential mediators.

METHODS AND MATERIALS: Our randomized double blind prospective placebo controlled study is to be carried out in 60 adult patients in the age group of 18-75 years who belonged to ASA class I and II scheduled for elective laparoscopic surgeries of duration >1 hour. They were assigned to two groups to receive either Clonidine 3ug/kg (Group C) and placebo-VIT C (Group P) orally with sips of water 90 min before estimated time of induction of anaesthesia. Same anaesthesia technique was used in both the groups. Intra abdominal pressure was kept between 12-14 mm Hg and End tidal CO2 between 30-35mmHg throughout the surgical procedure and airway pressure kept within normal limits. MAP was not allowed to increase more than 30% of baseline value. Isoflurane concentration were adopted to maintain haemodynamic stability.

RESULTS: The perioperative Heart Rate which was variable at each time interval was slower in the clonidine group in comparison with the placebo group.

The clonidine group had statistically significant low systolic and diastolic and mean blood pressure during pre induction, post intubation, pneumoperitoneum, post extubation and immediate postoperative period in PACU (post anaesthesia care unit) compared to the non-clonidine group.

The Isoflurane concentration required for maintaining acceptable perioperative hemodynamic stability was reduced in patients of the clonidine group.

During the intra-operative period (pneumoperitoneum) more patients in the placebo group suffered from hypertension which could not be managed with alteration of Isoflurane concentration alone and needed some antihypertensive treatment for intervention.

In immediate postoperative period, intensity of pain was less (as assessed by the time of first analgesic requirement by patient according to demand which was prolonged) in patients of clonidine group in comparison with the placebo group.

CONCLUSION: Premedication with low dose oral clonidine 3 ug/kg in patients undergoing laparoscopic surgery provides stable perioperative hemodynamics as revealed by less acute cardiovascular events that needed rescue drugs thus giving protection against stress response triggered by pneumoperitoneum. It also affords sparing effect on Isoflurane and good postoperative analgesia and lessens the severity of hemodynamic changes and complications during post-operative period.

Thus, low dose clonidine (3 ug/kg) can be reasonably recommended as a premedicant for all laparoscopic procedures.



KEYWORDS: Laparoscopic surgery, pneumoperitoneum, Intra abdominal pressure, Clonidine, Intra operative stress response, Post operative pain

I. INTRODUCTION

Laparoscopy has revolutionized surgeries and has become popular in the recent years. It has become the gold standard in any surgeries as it offers multiple benefits than conventional (open) surgery and has been promoted as a gentle surgery¹. But it presents several challenges for the anaesthesiologist. Compared to open procedures, laparoscopy is characterized by better maintenance of homeostasis².


The cardiovascular changes associated with laparoscopy (during pneumoperitoneumcarbon dioxide gas insufflation) are an increase in systemic vascular resistance, mean arterial pressure, pulmonary vascular resistance, myocardial filling pressures accompanied by a fall in the cardiac index and tissue perfusion.

These changes are not only related to the mechanical factors as they outlast the end of pneumoperitoneum. The neurohumoral factors like catecholamines, prostaglandins, the rennin aldosterone angiotensin system (RAAS), vasopressin are potential mediators.

Clonidine a centrally acting alpha₂ adrenenergic agonist is an antihypertensive medication and also has properties which are potentially beneficial for anaesthesia. It has been recently used for anaesthesia preedication, providing sedative, anxiolytic and analgesic effect and can reduce requirements of anaesthetics and analgesics.

It inhibits release of catecholamines and vasopressin which mediate the increase in systemic vascular resistance observed during pneumoperitoneum and thus modulates the hemodynamic changes induced by pneumoperitoneum. Hence clonidine premedication may prevent perioperative myocardial ischaemia patients at risk, related to increased orygen consumption induced by increased c workload by improving myocardial oxygen balance.

PHARMACOLOGY OF CLONIDINE-(C9-H9-C12-N3)



MECHANISM OF ACTION AND EFFECTS:

It is a synthetic centrally acting imidazoline derivative with predominantly alpha-2 adrenergic agonist activity. The overall effect is to decrease sympathetic activity, enhance parasympathetic tone and reduce circulatory catecholamines. Alpha 2 adrenergic agonists produce clinical effects when binded to the alpha-2 adrenergic receptors which are distributed widely in the body.

There are 3 subtypes of alpha-2 adrenergic receptors, alpha-2a, alpha-2b and alpha-2c, each of which may be uniquely responsible for some of the effects of alpha-2 adrenergic agonists.

A high density of alpha-2 adrenergic receptors has also been demonstrated in the vagus nerve, intermediolateral cell column and the substantia gelatinosa. The dorsal horn of the spinal cord contains alpha-2a adrenoreceptors while the primary sensory neurons contain both alpha-2a and alpha-2c subtypes of adrenoreceptors.

The ability of clonidine to modify the function of K+ channels in the CNS (cell membranes become hyperpolaroid) may be the mechanism for profound decreases in anaesthetic requirements produced by clonidine and other even more selective alpha2 adrenergic agonist such as dexmedetomidine.

PHARMACOKINETICS:

Clonidine can be administered by the enteric (oral and rectal), Neuraxial (epidural and subarachnoid), intravenous, intra-articular and transdermal routes. Oral clonidine is readily absorbed, has a 30-60 min onset of action and lasts for 6-12 hours.

It reaches peak plasma concentration in 60-90 min. It has an elimination t1/2 of 8-12 hours

II. MATERIAL AND METHODS

Our randomized double blind prospective placebo controlled study was carried out in 60 adult patients scheduled for elective laparoscopic surgeries of duration > 1 hour.

The study was approved by the institutional Ethical committee and written valid



informed consent was obtained from all the patients before being included in the study.

The study was conducted on 60 adult patients in the age group of 18-75 years and who belonged to ASA class I and II.

Patients with known allergy to Clonidine and NSAIDS, Patients taking clonidine, methyldopa, b-blocking drugs, mono-amine oxidase inhibitors were excluded.

Detailed pre anaesthetic evaluation was carried out with history, general examination and systemic examination including airway assessment. Vital parameters including pulse rate, respiratory rate, blood pressure, oxygen saturation was noted.

They were randomly assigned to two groups to receive either clonidine 3 ug /kg (group C) and placebo-vitamin C (group P) orally with sips of water 90 min before estimated time of induction of anaesthesia.

(GROUP C) with Tablet Vit C (ascorbic acid) as placebo (GROUP P) with sips of water confirming that the heart rate >45 min and systolic blood pressure > 100 mmHg (baseline reading).

PREMEDICATION

Premedication Given to all patients in each group with IV Midazolam 0.03 mg /kg, IV Fentanyl 2 mcg /kg, IV Ondansetron 0.05 - 0.15 mg/kg, IV Glycopyrolate 0.004 mg/kg if required(HR<45).

INDUCTION

In both groups, adequate preoxygenation was achieved by giving 100% oxygen for 3 min Induced was done with IV Pentothal sodium 5-7 mg/kg was given slowly and incremental doses of 25 mg. Endotracheal intubation was facilitated by IV succinylcholine 1.5 mg/kg. Direct laryngoscopy was done and an appropriate sized cuffed endotracheal tube was passed beyond the vocal cords. Air entry was checked by auscultation of chest and after confirming equal air entry, the cuff was inflated with air till there was no paratracheal leak palpated on either side of trachea.

MAINTENANCE

Maintenance with oxygen-nitrous oxide mixture (50:50) with adequate isoflurane. To facilitate IPPV neuromuscular blockade was achieved with Vecuronium bromide 0.08 mg/kg was given as a loading dose and 1/5 of the loading dose was repeated as and when neuromuscular blockade with the previous dose starts wearing off.

Adequate depth of anaesthesia and optimum hemodynamic and surgical conditions were maintained with 02 + N20 (50:50) + Isoflurane.

Intraabdominal pressure (IAP) was kept between 12-15 mmg throughout the surgical procedure.

After pneumoperitoneum necessary changes in ventilator settings (Tidal volume-decreased,

Respiratory frequency-increased, PEEP was added-5 cm H2O) were made to maintain normocapnia. Air entry was again checked after 10 min to confirm bilateral equality and adequacy at bases.

The tidal volume (Vt) and the ventilatory frequency (RR) was adjusted and intermittent positive pressure ventilation (IPPV) was continued by mechanical ventilator to maintain End Tidal CO2 between 30-35 mmHg and Peak Airway Pressures kept within normal limits between 18-22 cm of H2O.

RESCUE DRUGS USED WERE:

- MAP >110 OR 30% ABOVE BASELINE -Esmolol (500microgram/kg bolus -followed by 50 microgram/kg iv infusion), NTGnitroglycerine (1-2.5 mg/kg iv infusion),
- MAP <60 OR 30% BELOW BASELINE -Ephedrine 3-6 mg IV bolus doses.
- HR <40 Glycopyrrolate(0.2 mg) or atropine(0.5 mg)

After release of pneumoperitoneum and once the closure (peritoneal and abdominal wall) was started, the ventilator settings and patient position again changed to normal.

POST OPERATIVE PAIN RELIEF:

Was provided with 0.25% preservative and dextrose free Bupivacaine at port and drainage site as local infiltration (2cc at each port) just before closure of incision.

REVERSAL

At the end of surgery when spontaneous breathing pattern was established, neuromuscular blockade was reversed with IV neostigmine 0.05 mg/kg and IV glycopyrrolate 0.008 mg/kg. Patients were extubated after doing an oral suction and return of oropharyngeal reflexes and shifted to recovery.

IN THE RECOVERY ROOM (POST ANAESTHESIA CARE UNIT)

MODIFIED RAMSAY SEDATION SCALE:

- 1. Agitated, restless, irritable, anxious
- 2. Calm, tranquil, co-operative, oriented
- 3. Responds to oral commands.
- 4. Responds to light, glabellar tap, loud noise

5. Sluggish response to light, glabellar tap, loud noise.

6. No response



Heart Rate, Blood pressure, SpO2, End tidal CO2, End tidal Isoflurane, Dial concentration of Isoflurane vaporizer and Intraabdominal pressure were recorded at the following points of time:

- Prior to administration of clonidine (Baseline Reading)
- On arrival in operation (preinduction)
- Post intubation
- Before pneumoperitoneum
- After pneumoperitoneum
- After release of pneumoperitoneum
- After extubation
- Post op in recovery room for 2 hours

III. OBSERVATION AND RESULTS

The heart rate and blood pressure were noted before giving the medication (clonidine or placebo) and was recorded as baseline reading.

The heart rate and blood pressure were monitored preinduction, postintubation, just before creation of pneumoperitoneum (insufflation of CO2 gas), during pneumoperitoneum, after release of pneumoperitoneum (exsufflation), postextubation and 2 hrs postoperatively and compared with baseline value.

Following CO2 insufflation, normocapnia (End Tidal CO2 in a range of 35-40 mmHg) was maintained. Mean intraabdominal pressure was kept constant between 12-14 mmHg.

The anaesthetic management in our study was to maintain the perioperative hemodynamic parameters (HR and MAP) within 30% of the baseline values.

The mean heart rate (HR) and mean arterial pressure (MAP) in both the groups was compared. The End Tidal-Isoflurane was recorded in both the groups and was compared. The side effects in both groups C and P were noted and compared during intraoperative and postoperative period. The perioperative HR which was variable at each time interval was slower in the Clonidine group in comparison with the placebo group. The clonidine group had statistically significant low systolic and diastolic and mean blood pressure pre induction, post intubation, during pneumoperitoneum, post extubation and during their immediate postoperative period in PACU (post anaesthesia care unit) compared to the nonclonidine group.

None of the patients showed any evidence of ischaemia or arrhythmia intraoperatively. On the contrary there were episodes of bradycardia that needed acute drug intervention in some patients of clonidine group. 2 patients had to be given IV glycopyrrolate 0.2 mg.

Adverse events during postoperative period were nausea, vomiting, shivering and restlessness. These were less in group C in comparison with placebo premedication.

Both groups had mild somnolence, which was comparable.

No side effects other than bradycardia was observed in clonidine group, but no treatment was required as no patient had HR less than <45/min.

Intensity of pain was less (as assessed by the time of first analgesic requirement in immediate postoperative period was prolonged) in patients of clonidine group in comparison with the placebo group.

IV. STATISTICAL ANALYSIS

Chi square test and Mann-Whitney Test was applied for analysis of quantitative data and following were considered -

P Value:

>0.05 - not significant

< 0.05 - significant

<0.01 - very significant

< 0.001 - highly significant

Z score: of 1.96 would indicate that the locations of the distributions are different at p = 0.05.

	Group								
Variables	Clondine				Control				
	Mean	SD	Median	IQR	Mean	SD	Median	IQR	
ASA	1.27	0.45	1.00	1.00	1.27	0.45	1.00	1.00	
Dose of Clonidine- 3mcg/kg	154.07	39.90	152.00	91.25	158.10	26.11	154.50	41.25	
Duration of surgery	2.00	0.41	2.13	0.86	2.13	0.34	2.18	0.33	

Table No.1



	Group						
Variables	Clondine		Control		Mann-Whitney Test applied		
	Mean	Sum of	Mean	Sum of	Z- value	p- value	Difference is-
	Rank	Ranks	Rank	Ranks			
ASA	30.50	915.00	30.50	915.00	0.000	1.000	Not significant
Dose of							
Clonidine-	29.65	889.50	31.35	940.50	-0.378	0.706	Not significant
3mcg/kg							
Duration	27.73	832.00	33.27	998.00	-1.233	0.217	Not significant
of surgery							

Table No.2 COMPARISON OF HEART RATE AT VARIOUS TIME INTERVALS BETWEEN CLONIDINE AND CONTROL GROUPS

Heart rate at-	GROUP									
	CLONIDIN	ЛЕ			CONTROL					
	Mean	SD	Median	IQR	Mean	SD	Median	IQR		
Baseline	77.97	7.22	77.50	10.00	76.47	7.31	77.00	11.50		
Pre induction	72.77	8.10	72.00	12.00	78.13	7.09	77.50	10.25		
Post intubation	80.50	8.69	81.50	11.50	91.33	7.14	89.50	6.75		
Pre	71.20	8.28	72.50	11.75	75.30	6.60	74.50	11.25		
insufflations										
Post	69.87	8.23	69.50	11.00	77.80	6.99	77.00	12.25		
insufflation-15										
min										
Post	67.87	7.63	68.00	11.50	77.37	6.49	77.00	9.75		
insufflations-										
30 min										
Post	67.60	7.94	68.00	9.00	77.70	646	78.00	10.50		
insufflations-										
45 min										
Post	66.28	7.66	66.00	6.50	78.59	6.51	78.00	11.00		
insufflations-										
60 min										
Post	65.20	8.17	66.00	8.00	79.24	7.53	79.00	14.00		
insufflation-75										
min		0.10	67 .00	12.25				10.50		
Post	64.35	9.12	65.00	12.25	79.46	6.61	79.50	10.50		
insufflations-										
90 min	62.65	0.17	65.00	12.50	70.50	<i>5</i> 71	70.50	7.05		
Post	62.65	8.17	65.00	13.50	78.50	5.71	79.50	7.25		
insufflation-										
105 min Post	64.20	9.57	65.00	13.50	78.44	6.06	79.00	10.00		
insufflation-	04.20	9.57	03.00	15.50	/0.44	0.00	79.00	10.00		
120 min										
Exsufflation	67.27	7.73	67.00	8.00	73.13	5.78	72.00	8.00		
Post-	79.93	6.67	80.00	10.75	92.00	4.09	91.50	6.00		
extubation	17.75	0.07	50.00	10.75	12.00	1.07	71.50	0.00		
Post -op-30	71.77	5.84	70.00	6.00	78.50	6.83	78.50	14.25		
min	/ 1.//		, 0.00	0.00	, 0.50		, 0.20	1		
Post-op-60 min	69.87	6.10	70.00	6.25	80.33	5.74	81.00	10.00		
Post-op-90 min	68.13	6.77	68.00	5.00	78.03	4.58	78.50	4.75		
Post-op-120	68.53	4.61	68.00	5.00	75.53	3.80	75.00	6.00		
min										
	1	1	1	1	1	1	1	<u> </u>		

DOI: 10.35629/6018-06035060

|Impact Factorvalue 6.18| ISO 9001: 2008 Certified Journal Page 54



	GROU	P			Mann-Wh	itney Test a	applied
Heart rate at-	CLONI		CONTRO	L			
	Mean	Sum of	Mean	Sum of	Z-value	p-value	Difference is-
	Rank	Ranks	Rank	Ranks		1	
Baseline	32.02	960.50	28.98	869.50	-0.675	0.500	Not significant
Pre-induction	24.60	738.00	36.40	1092.00	-2.622	0.009	Significant
Post-intubation	20.18	605.50	40.82	1224.50	-4.582	4.61E-	Significant
						06	C
Pre-	26.57	797.00	34.43	1033.00	-1.748	0.081	Not significant
insufflation							C
Post-	22.23	667.00	38.77	1163.00	-3.674	0.0002	Significant
insufflation-15							
min							
Post-	20.55	616.50	40.45	1213.50	-4.421	9.82 E-	Significant
insufflation-30						06	
min							
Post-	20.22	606.50	40.78	1223.50	-4.568	4.93 E-	Significant
insufflation-45						06	_
min							
Post-	18.12	525.50	40.88	1185.50	-5.137	2.80 E-	Significant
insufflation-60						07	
min							
Post-	15.56	389.00	37.79	1096.00	-5.187	2.14 E-	Significant
insufflation-75						07	
min							
Post-	12.93	258.50	32.77	917.50	-4.845	1.27 E-	Significant
insufflation-90						06	
min							
Post-	9.88	168.00	25.67	462.00	-4.562	5.07 E-	Significant
insufflation-						06	
105 min							
Post-	6.50	65.00	13.89	125.00	-2.860	0.0042	Significant
insufflation-							
120 min							
Exsufflation	22.60	678.00	38.40	1152.00	-3.509	0.0004	Significant
Post-	17.02	510.50	43.98	1319.50	-5.988	2.12 E-	Significant
extubation						09	
Post-op-30 min	21.97	659.00	39.03	1171.00	-3.800	0.0001	Significant
Post-op-60 min	18.63	559.00	42.37	1271.00	-5.273	1.35 E-	Significant
						07	
Post-op-90 min	18.42	552.50	42.58	1277.50	-5.379	7.49 E-	Significant
						08	
Post-op-120	18.88	566.50	42.12	1263.50	-5.171	2.33 E-	Significant
min						07	

Table No.3

COMPARISON OF MEAN ARTERIAL PRESSURE AT VARIOUS TIME INTERVALS BETWEEN CLONIDINE AND CONTROL GROUPS M

Mean arterial	GROUP	GROUP							
pressure at-	CLONIDIN	ΙE			CONTROL				
	Mean	SD	Median	IQR	Mean	SD	Median	IQR	
Baseline	94.64	7.32	95.33	13.33	94.00	6.06	93.67	9.25	
Pre induction	90.16	6.57	90.33	11.50	94.68	7.71	92.83	9.33	
Post intubation	91.94	7.24	93.33	13.33	111.19	7.84	108.00	11.50	
Pre insufflations	84.70	6.08	84.33	10.33	91.28	4.53	91.17	6.50	

DOI: 10.35629/6018-06035060

|Impact Factorvalue 6.18| ISO 9001: 2008 Certified Journal Page 55



	06.62	F 00	06.50	0.25	112.11	0.25	111.02	7.00
Post	96.60	5.90	96.50	9.25	113.11	8.35	111.83	7.33
insufflation- 15								
min Da at	02.62	E 07	01.50	075	114 61	11.16	111 67	10.09
Post insufflations-30	92.62	5.87	91.50	8.75	114.61	11.16	111.67	10.08
min	00.07	6.25	90.50	0.02	110.74	0.51	100.50	0.75
Post	90.07	6.25	89.50	8.83	110.74	9.51	108.50	8.75
insufflations-45								
min	88.20	4 1 1	00.50	6.25	111.00	10.00	107.00	11.00
Post insufflations-60	00.20	4.11	88.50	0.23	111.80	10.69	107.00	11.00
min	85.48	2.05	85.33	5.17	108.79	7.81	107.33	7.17
Post insufflation-75	03.40	3.95	83.33	5.17	108.79	7.01	107.55	/.1/
min Doct	9616	4.88	95.00	7.67	109 50	7.56	106.50	6.92
Post insufflations-90	86.46	4.88	85.00	/.0/	108.50	1.30	100.30	6.83
min								
Post	87.61	5.41	86.67	11.50	108.49	8.42	105.67	11.33
insufflation-105	07.01	3.41	00.07	11.30	100.49	0.42	105.07	11.55
min Post	86.15	4.10	86.67	6.83	107.85	9.51	103.67	19.67
insufflation-120	00.15	4.10	00.07	0.05	107.05	7.51	105.07	17.07
min								
Exsufflation	84.64	6.18	82.83	6.25	97.36	5.49	97.33	5.92
Post-extubation	95.71	4.43	95.00	6.17	112.08	7.25	111.00	6.25
	89.78	5.20	93.00	7.33	98.03	5.15	97.00	9.33
Post –op-30 min Post-op-60 min	87.11	4.16	87.00	6.33	98.03 99.18	5.03	100.33	9.50
	85.09	5.16		7.17	96.33	3.86	95.67	6.33
Post-op-90 min	85.30	4.70	84.67 83.33					
Post-op-120 min	85.50	4.70	83.33	8.33	93.36	4.12	92.33	4.83
111111	GROU	D			Monn Wi	hitney Test	topplied	
Heart rate at-	CLONI		CONTR	OI	Iviaiiii- vvi	intiley res	applied	
mean rate at-		Sum of			Z-value		Differenc	- ia
	Mean Rank	Ranks	Mean Rank	Sum of Ranks	Z-value	p- value	Difference	e is-
Baseline		956.00			-0.607		Noteioni	ficent
	31.87		29.13	874.00		0.544	Not signi	
Pre-induction	25.67	770.00	35.33	1060.00	-2.146	0.032	Significan	
Post-intubation	15.73	472.00	45.27	1358.00	-6.551	5.71E-	Significat	u
Pre-insufflation	21.55	646.50	39.45	1183.50	-3.972	11 7.12E-	Significa	nt
Pre-insullation	21.55	040.30	39.45	1185.50	-3.972		Significa	nt
Post-	16.40	402.00	11 60	1338.00	6 250	05 2.05E	Cionifia:	
Post- insufflation-15	16.40	492.00	44.60	1558.00	-6.256	3.95E-	Significat	n
min						10		
Post-	15.80	474.00	45.20	1356.00	-6.521	6.99E-	Significat	nt
insufflation-30	13.00	4/4.00	43.20	1550.00	-0.321	6.99E- 11	Significal	n
min						11		
Post-	15.80	474.00	45.20	1356.00	-6.522	6.95E-	Significat	at
insufflation-45	13.00	4/4.00	43.20	1550.00	-0.322	0.95E- 11	Significal	n
min						11		
Post-	14.50	406.00	43.00	1247.00	-6.483	9.01E-	Significat	nt
insufflation-60	14.30	400.00	45.00	1247.00	-0.403	9.01E- 11	Significal	n
min				1		11		
Post-	13.00	325.00	40.00	1160.00	-6.291	3.16E-	Significat	nt
insufflation-75	13.00	525.00	40.00	1100.00	-0.291	3.16E- 10	Significal	n
msumation-/J	1					10	1	



min							
Post- insufflation-90 min	10.05	191.00	33.46	937.00	-5.747	9.09E- 09	Significant
Post- insufflation-105 min	9.29	158.00	26.74	508.00	-4.961	7.02E- 07	Significant
Post- insufflation-120 min	5.00	45.00	14.00	126.00	-3.578	0.0003	Significant
Exsufflation	17.98	539.50	43.02	1290.50	-5.555	2.78E- 08	Significant
Post-extubation	16.12	483.50	44.88	1346.50	-6.382	1.74E- 10	Significant
Post-op-30 min	19.72	591.50	41.28	1238.50	-4.788	1.68E- 06	Significant
Post-op-60 min	16.42	492.50	44.58	1337.50	-6.253	4.02E- 10	Significant
Post-op-90 min	16.63	499.00	44.37	1331.00	-6.156	7.45E- 10	Significant
Post-op-120 min	18.75	562.50	42.25	1267.50	-5.219	1.80E- 07	Significant

Table No 4

	CDOUD			10	ible No 4						
X7 11	GROUP	n re				GOVER					
Variables	-	ONIDINE					CONTROL				
	Mean	SD	Median		IQR	Mean		D		dian	IQR
SEDATION	1.43	0.50	3.0	00	1.00	1.57	0.	.57	3.5	0	1.00
SCORE- 1											
HOUR POST											
OP											
TIME OF	2.34	0.54	2.2	28	0.66	1.11	0.	.77	1.0	0	1.71
FIRST											
ANALGESIA											
REQUIREME											
NT											
(OPIOIDS/NS											
AIDS)	-										
	Group					Mann-V	Nhi	itney Test	appl	ied	
Variables	CLONID			CONT						1	
	Mean		of	Mean	Sum	Z-value	;	p-value		Differ	ence is
	rank	Ranks		rank	of						
					Rank						
					S						
SEDATION	24.13	724.00		36.87	904.	-2.971		0.003		Signif	ïcant
SCORE- 1					00						
HOUR POST											
OP											
TIME OF	45.50	1365.00)	15.50	465.	-6.660		2.73E-1	1	Signif	ïcant
FIRST					00						
ANALGESIA											
REQUIREME											
NT											
(OPIOIDS/NS											
AIDS)											



V. DISCUSSION

Pneumoperitoneum during laparoscopic surgery, especially carbon dioxide gas insufflation, produces significant hemodynamic changes in healthy patients. Hypertension and tachycardia accompanied by increased sympathetic nervous system activity may lead to an imbalance between myocardial oxygen demand and supply. The cardiovascular changes associated with laparoscopy is an increase in systemic vascular resistance (SVR), mean blood pressure(MAP) and myocardial filling pressures, accompanied by a fall in the cardiac index (CI). Heart rate does not change or increases only slightly.⁶

The increase in SVR is not only related to mechanical factors but also neurohumoral factors as it outlasts the end of pneumoperitoneum. The neurohumoral factors like catecholamines (norepinephrine and epinephrine), prostaglandins, the renin angiotensin system especially vasopressin are potential mediators. These surges are reasonably expected to cause an increase in systemic vascular resistance and mean arterial pressure. These changes can be detrimental especially in elderly patients.

Clonidine premedication has been proved to prevent perioperative myocardial ischemia by improving myocardial oxygen balance.⁸

It causes a reduction of tonic sympathetic outflow (documented to decrease plasma catecholamine levels) and prevents activation of RAAS (renin angiotensin aldosterone system) seen as decreased plasma renin activity. Oral clonidine premedication decreases the release of proinflammatory cytokines interleukin (IL)-6, IL-1b and tumour necrosis factor and stress hormones cortisol and adrenocorticotropic hormone (ACTH). The drug has been recently used for anaesthetic premedication, providing sedative, anxiolytic and analgesic effects that reduce the requirement for IV and volatile anaesthetics and narcotics.

Clonidine smoothed the changes in arterial pressure, HR, SVR and cardiac output during laparoscopic surgery (as seen in many studies), which are caused by CO2 PP. These benefits are mediated by a reduction of neurohumoral secretion secondary to stress induced sympatho-adrenal hyperactivation.

Clonidine premedication prevents sympathetic hyperactivity but does not suppress hypothalamo pituatary adrenocortical responses in patients undergoing laparoscopy.

Clonidine effects are not only limited to the pre and intra-operative period but also extend to postoperative period. The only limitation is that it cannot be applied to patients presenting for emergency surgery.

Joris et al used very high dose of clonidine - 8 mcg/kg for reducing the level of catecho lamine and vasopressin following PNO. Malek et al used 150 mcg/kg of clonidine as IV infusion and intramuscularly while Sung et al and Yu et al used 150 ug/kg of oral clonidine as premedication for maintenance of hemodynamic stability during PNO.

MEAN HEMODYNAMIC VALUES WERE AS FOLLOWS-

Thus clonidine premedication was able to effectively blunt the cardiovascular response to surgical stress especially pneumoperitoneum and achieve hemodynamic stability. Similar findings were reported by Aho et al ,Joris et al, Malek et al, Sung et al. Yu at al and Laiselmi et al.

			Sung et al, Y	u et al and Laisalmi et al.
			CLONIDINE	CONTROL GROUP
PRE	HR			78.13+/-7.09
INDUCTION	72.77+	-/-8.1		94.68+/-7.71
	MAP			
	90.16+	-/-6.57		
POST	HR			91.33+/-7.14
INTUBATION	80.50+	-/-8.69		111.19+/-7.84
	MAP			
	91.94+	-/-7.24		
	HR	30 MIN	67.87+/-7.63	77.37+/-6.49
		60 MIN	66.28+/-7.66	78.59+/-6.51
POST		90 MIN	64.35+/-9.12	79.46+/-6.61
INSUFFLATION	MAP	30 MIN	92.62+/-5.87	114.61+/11.16
		60 MIN	88.20+/-4.11	111.80+/10.69
		90 MIN	86.46+/-4.88	108.50+/-7.56
POST	HR			92.00+/-4.09
EXTUBATION	79.93+	-/-6.67		112.08+/-7.25
	MAP			

DOI: 10.35629/6018-06035060

|Impact Factorvalue 6.18| ISO 9001: 2008 Certified Journal Page 58



	95.71+/-4.43		
POST OPERATIVE	HR 30 MIN 1.77+/-5.84	7	78.50+/-6.83 80.33+/-5.74
	60 MIN 6.10	69.87+/-	
	MAP 30 MIN 5.20	89.78+/-	99.18+/-5.03 96.33+/-3.86
	60 MIN 4.16	87.11+/-	

Thus clonidine premedication was able to effectively blunt the cardio vascular response to surgical stress especially pneumoperitoneum and achieve hemodynamic stability. Similar findings were reported by Aho et al. Joris et al, Malek et al. Sung et al. Yu et al and Laisalmi et al.

In our study the depth of anaesthesia was viewed by the reflection of cardiovascular variables (HR, MAP) at an inspired isoflurane concentration greater than 0.6-0,8%. Electroencephalography was not applied to monitor the neurophysiologically defined depth of anaesthesia.

Entholzner et al showed that premedication with clonidine would result in a synergistic effect on the central nervous system well correlative which was with the neurophysiologically defined depth of anaesthesia. As clonidine would blunt the sympathetic outflow, evaluation of anaesthetic depth solely based o the cardiovascular response to surgical stress could be unreliable and unrealistic and patients premedicated with clonidine would likely be subjected to inadequate anaesthesia. However the fact that none of our patients in the clonidine group had intraoperative awareness or recall of introperative events might suggest that the depth of anaesthesia in these patients was sufficient or acceptable.

Anxiolysis in the clonidine group was better than in the placebo group. Patients of clonidine group were much calmer than patients of the control group. These findings were also reported by Beer et al.

No patients with Clonidine premedication suffered from respiratory depression in our study, which coincided with Sung cs et al, Jarvis et all and Prause et al.

The number of analgesics required in the placebo group was also higher than in the clonidine group. Only 4 patients of the clonidine group had to be given tramadol within 2 hours postop as an additional analgesic in contrast to 22 patients in the non-clonidine group who received the same This postoperative anaigesic effect of clonidine in our study was in agreement with reports by Mikawa et al, Samso et al, Segal et al and Behamou et al. Despite the fact that clonidine was not a pure analgesic and 150 ug oral Clonidine premedication without another postoperative supplement could not completely relieve postoperative pain, clonidine premedication provided additional postoperative analgesia. The decrease in patient demand analgesia could also improve post-operative care.

Thus clonidine, an alpha agonist, has been shown to decrease peripheral sympathetic outflow without increasing the baroreceptor reflex and decreases the anaesthetic requirement.

Thus it appears to be an appropriate drug for premedication in laparoscopic surgery to fulfill the anaesthetic aims of reducing stress response and subsequent adverse events.

VI. CONCLUSION

Premedication with oral low dose clonidine provides stable perioperative hemodynamics as revealed by less acute cardiovascular events that needed rescue drugs and protection against stress response triggered by pneumoperitoneum in patients undergoing laparoscopic surgery.

Thus low dose oral clonidine 3mcg/kg can be reasonably recommended as a routine premedication for all laparoscopic procedures.

BIBLIOGRAPHY

- [1]. Das, Mrinmoy1; Ray, Manjushree2,; Mukherjee, Gauri3. HAEMODYNAMIC CHANGES DURING LAPAROSCOPIC CHOLECYSTECTOMY: EFFECT OF CLONIDINE PREMEDICATION. Indian Journal of Anaesthesia 51(3):p 205-210, May–Jun 2007.
- [2]. Singh S, Arora K. Effect of oral clonidine premedication on perioperative haemodynamic response and postoperative analgesic requirement for patients undergoing laparoscopic cholecystectomy. Indian J Anaesth. 2011 Jan;55(1):26-30.



doi: 10.4103/0019-5049.76583. PMID: 21431049; PMCID: PMC3057241.

- [3]. Hall DL, Tatakis DN, Walters JD, Rezvan E. Oral Clonidine Pre-treatment and Diazepam/Meperidine Sedation. Journal of Dental Research. 2006;85(9):854-858. doi:10.1177/154405910608500915
- [4]. Naude GP, Ryan MK, Pianim NA, Klein Lippmann M, Bongard SR. FS Comparative stress hormone changes during helium versus carbon dioxide laparoscopic cholecystectomy. I Laparoendosc Surg. 1996 Apr;6(2):93-8. doi: 10.1089/lps.1996.6.93. PMID: 8735046.
- [5]. Quíntin L, Cicala R, Kent M, Thomsen B. Effect of clonidine on myocardial ischaemia: a double-blind pilot trial. Can J Anaesth. 1993 Jan;40(1):85-6. doi: 10.1007/BF03009332. PMID: 7980723.
- [6]. Kabakchiev C, Valverde A, Singh A, Beaufrère H. Cardiovascular and respiratory effects of carbon dioxide pneumoperitoneum in the domestic rabbit (Oryctolagus cuniculus). Can J Vet Res. 2020 Apr;84(2):108-114. PMID: 32255905; PMCID: PMC7088512.
- [7]. Safran DB, Orlando R 3rd. Physiologic effects of pneumoperitoneum. Am J Surg. 1994 Feb;167(2):281-6. doi: 10.1016/0002-9610(94)90094-9. PMID: 8135322.
- [8]. Wahba RW, Béïque F, Kleiman SJ. Cardiopulmonary function and laparoscopic cholecystectomy. Can J Anaesth. 1995 Jan;42(1):51-63. doi: 10.1007/BF03010572. PMID: 7889585.
- [9]. Hirvonen EA, Nuutinen LS, Kauko M. Hemodynamic changes due to Trendelenburg positioning and pneumoperitoneum during laparoscopic hysterectomy. Acta Anaesthesiol Scand. 1995 Oct;39(7):949-55. doi: 10.1111/j.1399-6576.1995.tb04203.x. PMID: 8848897.
- [10]. Hirvonen EA, Poikolainen EO, Pääkkönen Nuutinen The ME, LS. adverse hemodynamic effects of anesthesia, headtilt. and carbon dioxide up pneumoperitoneum during laparoscopic cholecystectomy. Surg Endosc. 2000 Mar;14(3):272-7. doi: 10.1007/s004640000038. PMID: 10741448.
- [11]. Ivankovich AD, Miletich DJ, Albrecht RF, Heyman HJ, Bonnet RF. Cardiovascular

effects of intraperitoneal insufflation with carbon dioxide and nitrous oxide in the dog. Anesthesiology. 1975 Mar;42(3):281-7. doi: 10.1097/00000542-197503000-00008. PMID: 123134.

- Joris JL, Noirot DP, Legrand MJ, Jacquet NJ, Lamy ML. Hemodynamic changes during laparoscopic cholecystectomy. Anesth Analg. 1993 May;76(5):1067-71. doi: 10.1213/00000539-199305000-00027. PMID: 8484509.
- [13]. Schilling MK, Redaelli C, Krähenbühl L, Signer C, Büchler MW. Splanchnic microcirculatory changes during CO2 laparoscopy. J Am Coll Surg. 1997 Apr;184(4):378-82. Erratum in: J Am Coll Surg 1997 Oct;185(4):423. PMID: 9100683.
- [14]. Feig BW, Berger DH, Dougherty TB, Dupuis JF, Hsi B, Hickey RC, Ota DM. Pharmacologic intervention can reestablish baseline hemodynamic parameters during laparoscopy. Surgery. 1994 Oct;116(4):733-9; discussion 739-41. PMID: 7940173.